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ABSTRACT
B cells appear to play a role in chronic graft-versus-host disease (cGVHD) as shown in murine models and the
success of anti-CD20 B cell antibody treatment in humans. Recent studies have shown that immunostimulatory
microbial CpG-DNA splenic responses were enhanced in murine GVHD. We hypothesized that CpG-induced
B cell responses are increased in human cGVHD. Newly diagnosed cGVHD patients enrolled on the COG
protocol ASCT0031 were divided into early (3-8 months postblood and marrow transplant [BMT]) and late
(>9 months post-BMT) onset groups and compared to time-matched control BMT patients. A significantly
greater percentage of phosphorothioate (PS)-modified CpG stimulated B cells from cGVHD patients dem-
onstrated an increased expression of CD86 compared to controls (P  .0004). This response had a significant
correlation between B cell TLR9 expression (r2  0.65; P  .002) and CD86 upregulation using the entirely
TLR9-dependent native phosphodiester CpG (P  .003). The PS-modified CpG response at 2 months after
initiation of cGVHD therapy demonstrated a trend toward predicting therapeutic response at 9 months
post-BMT (P  .07). These findings suggest that an increased number of B cells, primed for a TLR9 response,
may play a role in the pathophysiology of cGVHD.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Allogeneic blood and marrow transplant (BMT) is
sed to treat an increasing number of malignant and
onmalignant conditions. Acute and chronic graft-ver-
us-host disease (GVHD) remain major obstacles to
uccessful transplant outcome. The complex patho-
hysiology of chronic GVHD (cGVHD) is not fully
nderstood as the development of uniform diagnos-
ic criteria is complicated by highly pleiotropic clin-
cal manifestations [1]. It has been established, how-
ver, that activated T cells are the main mediators of
GVHD [2]. Despite some efﬁcacy of T cell depletion b
86or decreasing cGVHD in both animals [3] and hu-
ans [4], this approach is also associated with an
ncreased risk of infection [5], leukemic relapse [6],
nd hematopoietic stem cell graft failure [7].
There is strong evidence supporting the impor-
ance of activated antigen-presenting cells (APCs) in
he development of cGVHD [8,9]. T cell activation in
his context depends upon functional class II major
istocompatibility complex [10] and presentation of co-
timulatory molecules such as CD80 and CD86 by pro-
essional APCs [11]. B cells, acting as APCs, appear to be
nstrumental in T cell priming to minor histocompati-
ility antigens and development of cGVHD in mice [12]
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TLR9 Response in Chronic GVHD 387nd humans [13]. This conclusion is supported by the
bservation that in vivo depletion of B cells with Ritux-
mab can suppress the progression of complicated
GVHD [14].
In addition to mediating adaptive immune re-
ponses, APCs are able to recognize the presence of
icroorganisms through the detection of conserved
athogen-associated molecular patterns (PAMP) and
apidly initiate tailored responses to these danger sig-
als. Although it has been established that lipopoly-
accharides can alter the post-BMT environment and
ncrease the risk of acute GVHD (aGVHD) [15], the
ole of PAMP-mediated immune activation of APCs
n the context of cGVHD has not been extensively
nvestigated. However, there is increasing evidence
hat microbial products may potentially contribute to
GVHD development and disease maintenance as
upported in animal models. Both microﬂoral decon-
amination [16] and blockade of PAMP-inducible co-
timulatory molecules such as CD40 to CD40L
CD152) [17] or B7.1 (CD80) and B7.2 (CD86) [18]
o CD28 in mice are effective in decreasing GVHD.
dditionally, 4-aminoquinolines, such as chloroquine
nd hydroxychloroquine, which potently suppress the
mmunostimulatory activity of CpG-rich microbial
NA [19], have been successfully used clinically to
reat cGVHD [11,12].
Immunostimulatory CpG motifs in microbial
NA are a class of PAMP [20,21] that is emerging as
eing involved in various autoimmune diseases [22,23]
f which features of cGVHD resemble, in contrast
ith aGVHD. Synthetic PS modiﬁed immunostimu-
atory CpGs, similar to microbial immunostimulatory
NA, are recognized in a sequence-dependent man-
er by intracellularly located Toll-like receptor 9
TLR9) [24,25], which, in humans, is primarily ex-
ressed by B cells and some dendritic cell subsets [26].
t has been shown that, whereas synthetic CpGs are
apable of augmenting murine graft-versus-leukemia
esponses after experimental BMT, it also aggravates
VHD severity [27]. Our group has shown in a sim-
lar mouse model that splenocytes from mice with
VHD have an exaggerated mitogenic and interleu-
in 6 response to synthetic CpG compared to synge-
eic transplant controls, and that both splenic cell
pG responsiveness and GVHD were signiﬁcantly
meliorated by chloroquine [28]. In conjunction with
he success of hydroxychloroquine [20] and B cell
blation [14] as treatments for human cGVHD, CpG-
ediated stimulation of B cells through TLR9 may be
mportant in cGVHD. To address this question we
nvestigated B cell responses to modiﬁed synthetic
pG and native synthetic CpG, which more closely
esembles the natural ligand of TLR9, in pediatric
atients postallogeneic hematopoietic stem cell trans-
lantation, who were diagnosed with cGVHD. fATERIALS AND METHODS
atients
Samples were obtained from patients enrolled in
he Children’s Oncology Group trial, ASCT0031.
he study was a Phase III randomized, placebo-con-
rolled, double-blinded trial evaluating 2 treatment
egimens for patients with newly diagnosed extensive
GVHD. Patients with cGVHD received a standard
egimen of cyclosporine and alternate-day prednisone
ith either hydroxychloroquine or placebo. Patients
nrolled were aged 1–29.9 years old at the time of
tudy entry. The controls were enrolled by centers for
atients that did not have cGVHD. The enrollment
as entirely voluntary by each center, and there was
o attempt to establish matched controls for the
GVHD subjects enrolled. The decision to allow a
enter to participate in control enrollment was not
ased on the characteristics of the patients enrolled,
ut on the resources available to identify and follow
uch individuals. Newly diagnosed extensive cGVHD
as documented with biopsy conﬁrmation of at least 1
rgan system (eg, lip, skin, liver) and either (1) gen-
ralized skin involvement; or (2) localized skin in-
olvement and/or liver dysfunction plus at least 1 of
he following: liver histology showing chronic aggres-
ive hepatitis, bridging necrosis, or cirrhosis; eye in-
olvement (Schirmer’s test with 5 mm wetting); in-
olvement of minor salivary glands or oral mucosa on
ip biopsy; or involvement of any other target organs;
r (3) involvement of at least 2 target organs. Periph-
ral blood samples in patients with cGVHD were
ollected at study entry and at 2, 6, and 12 months
fter study entry. Peripheral blood was also collected
rom control postallogeneic BMT patients without
ocumented cGVHD at 6 and 12 months after trans-
lantation. There were a total of 54 patients with
GVHD and 28 control patients without cGVHD
vailable for this study. Because numerous immuno-
ogic studies were performed and the described studies
equired relatively high cell numbers, only 25
GVHD and 16 controls had sufﬁcient sample cell
ounts to allow for the studies presented in this report
o be included. Patient characteristics are shown for
he study population in Table 1. Two control samples
ere collected at 6 months and 12 months post-BMT
n patients who did not have cGVHD to address the
otential confounding factor of immune reconstitu-
ion after BMT. A time-matched comparison was per-
ormed with days post-BMT at the time of cGVHD
iagnosis used to divide the patients into an early
nset (3-8 months; n 36, mean 5.7 1.7 months)
r late onset (9 months; n  15, mean  14.3  6
onths) group to allow comparison against samples
rom control patients drawn at 6 and 12 months post-
ransplant, respectively. All blood samples collected
or analysis were done before initiation of protocol
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K. She et al.388herapy on the study, except for 1 analysis that was
orrelated with therapeutic response done on samples
ollected 2 months after initiation of protocol treat-
ent.
atient Characteristics
Patients with cGVHD and without (controls)
ere compared for differences in age, sex, donor
ource, donor type, and presence of aGVHD (Table
). There was a signiﬁcant difference between patients
ith and without cGVHD for older recipient age
13.2  5.2 versus 7.2  5.9; P  .006) and source of
onor hematopoietic stem cells (40%, 56%, and 4%
ersus 50%, 6%, and 44%, bone marrow, peripheral
lood, and cord blood respectively; P  .0005) in
atients who developed cGVHD. The sex of the re-
ipient did not inﬂuence the development of cGVHD
P  .15); neither did an unrelated donor source (P 
53). As expected, the presence of aGVHD in the ﬁrst
months after BMT had a very signiﬁcant correlation
ith development of cGVHD (P  .0001). As noted
reviously, the evaluations performed in this study
ere not performed on all patients that entered the
linical trial, ASCT0031, because of prioritization of
he small cell numbers in patient samples obtained in
pediatric trial. A similar evaluation of the clinical
haracteristics on all patients enrolled in ASCT0031
evealed no difference in clinical characteristics com-
able 1. Patient Characteristics
Chronic
GVHD*
(n  25)
No GVHD
(Controls)
(n  16) P value
ge
Median (range) 13 (2–21) 4 (1–19) 0.006†
Mean (SD) 13.2 (5.2) 7.2 (5.9) 0.002‡
ex 0.15§
Male 18 (22%) 8 (50%)
Female 7 (28%) 8 (50%)
onor source 0.0005
Bone marrow 10 (40%) 8 (50%)
Peripheral blood 14 (56%) 1 (6%)
Umbilical cord blood 1 (4%) 7 (44%)
onor type 0.53‡
Related donor 15 (60%) 8 (50%)
Unrelated donor 10 (40%) 8 (50%)
cute GVHD 0.002
Yes 14 (56%) 1 (6%)
No 11 (44%) 15 (94%)
The number of patients presented represents those that had evalu-
able samples and not all patients enrolled in study. This table
only includes control patients who had evaluable samples sub-
mitted at 6 or 12 months posttransplant.
Wilcoxon rank sum test.
F-test.
Chi-square test.
Fisher’s exact test.ared to the data in Table 1. Tells and Tissue Culture
Up to 1 mL/kg of peripheral blood (PB) was
ollected in sodium-citrate heparin glass tubes from
atients enrolled in the Children’s Oncology Group
tudy ASCT0031 at the time of cGVHD diagnosis
efore receiving treatment or at regular intervals post-
ransplant from control patients who had undergone
MT but had not developed cGVHD. Peripheral
lood samples were shipped or stored overnight at
mbient temperature prior to harvesting peripheral
lood mononuclear cells (PBMCs). Upon receipt of
amples, they were evaluated on a prioritization ap-
roach with immunophenotyping ﬁrst, T cell func-
ional studies second, and CpG response third. This
rioritization schema and the fact that the pediatric
amples were a small volume resulted in only approx-
mately 1/2 of samples (25 of 54 cGVHD and 14 of 28
ontrols) having sufﬁcient cell numbers to allow for
pG response evaluation. Brieﬂy, PB was layered over
icoll-Paque™ Plus (Amersham Pharmacia Biotech
B, Upsala, Sweden) and centrifuged at 1500 rpm for
0 minutes at 19°C in an IEC Centra GP8R centri-
uge. Mononuclear cells at the interface were removed
nd washed with phosphate-buffered saline (PBS) 2%
etal bovine serum (FBS), and resuspended in com-
lete RPMI (Invitrogen Life Technologies, Carlsbad,
A) at 2  106 cells/mL. In all experiments involving
ligonucleotide (ODN) stimulation, 1  106 cells
ere incubated with or without 6 g/mL ODN for 48
ours prior to analysis. The ODNs used include PS
PS)-modiﬁed CpG 2006 (t*c*g* t*c*g* t*t*t* t*g*t*
*g*t* t*t*t* g*t*c* g*t*t*), phosphodiester (PD) CpG
006 (tcg tcg ttt tgt cgt ttt gtc gtt), control PS-
odiﬁed GpC 2137 (t*t*g* c*t*g* t*t*t* t*g*c* t*g*t*
*t*t* g*c*t* g*c*t*), or control PD GpC 2137 (ttg ctg
tt tgc tgt ttt gct gct). All ODN were obtained from
igma-Aldrich (St. Louis, MO). All ODN tested neg-
tive for endotoxin contamination with Lumulus
mebocyte Lysate PYROGENT® Plus (Cambrex Bio
cience, Walkersville, MD). The activity of PS mod-
ﬁed CpG 2006 used in this study has been previously
xtensively analyzed [29]. In experiments involving
eptidoglycan (PG) stimulation, 1  106 cells were
ncubated with or without 10 g/mL PG (Fluka Pro-
uction GmvH, Buchs, SG) for 48 hours prior to
nalysis. In experiments involving lipopolysaccharide
LPS) stimulation, 1  106 cells were incubated with
r without 1 g/mL LPS (Sigma Aldrich).
mmunophenotyping
Four-color ﬂow cytometry was performed on a
ACSCalibur™ ﬂow cytometer (Becton Dickinson,
ranklin Lakes, NJ). For analysis of cell surface mol-
cules, all samples were labeled with directly conju-
ated ﬂuorescent antibodies at 4°C for 20 minutes.
he samples were then washed and resuspended in
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TLR9 Response in Chronic GVHD 389BS-1.5% paraformaldehyde and analyzed immedi-
tely. All antibodies were obtained from BD Pharm-
ngen (San Diego, CA). The relevant labeled isotype
ontrol antibodies were included in all experiments.
ll cells with a staining intensity higher than the upper
imit obtained using the isotype control were consid-
red positive. Analysis was performed using CellQuest
oftware (Becton Dickinson) after gating on the spe-
iﬁc population according to forward and side scatter
nd pan-subpopulation surface molecule expression.
epletion of Adherent Cells
PBMC were incubated in complete RPMI in 50
L Falcon (BD Bioscience, San Jose, CA) polystyrene
ulture plates at 37°C for 3 hours at 5% CO2. Non-
dherent cells were harvest by pipetting and analyzed
y FACS. The presence of CD14monocytes, Lin,
LA-DR, CD11c myeloid dendritic cells, and
in, HLA-DR, CD123 plasmacytoid cells were
1%, 0.1%, and 0.1%, respectively.
Cell Purification
PBMCs were isolated over Ficoll-Paque™ Plus as
escribed above and resuspended at 5  107 cells/mL
n PBS 4% FBS. B cells were isolated using StemSep
uman B cell Enrichment Cocktail (Stem Cell Tech-
ologies Inc., Vancouver, Canada). Puriﬁed B cells
ere resuspended at 2  106 cells/mL in complete
edia. B cells were 95% pure as determined by ﬂow
ytometry.
roliferation Assays
Assays were set up in triplicate in complete media
sing round bottom 96-well plates; 1  105 B cells
ere plated in each well. Cell stimulation was per-
ormed with the same reagents and concentrations as
escribed above. Plates were incubated for 28 hours at
7°C and then 3H-thymidine was added to each well
t a ﬁnal concentration of 1 Ci/mL and incubation
as continued for an additional 20 hours. DNA was
hen harvested using a Mach III M harvester (Tomtec,
amden, CT) and 3H-thymidine incorporation was
ounted on a 1450 Microbeta liquid scintillation
ounter (Wallac Trilux, Turku, Finland) using Wallac
450 Microbeta windows workstation software (ver-
ion 2.70.004).
uantitative RT-PCR
Total RNA was extracted from puriﬁed B cells on
amples with sufﬁcient cell numbers using Trizol re-
gent (Gibco BRL, Rockville, MD). Following
NAse I treatment, cDNA was synthesized with 1 g
f total RNA using oligo dT primers and Superscript
I reverse transcriptase (Invitrogen Life Technolo-
ies). Real-time quantitative PCR was performed us-
ng the TaqMan system (Applied Biosystems, Foster Pity, CA). The expression level of TLR9 and internal
eference TATA-box binding protein (TBP) was mea-
ured by PCR using TaqMan probes labeled with
AM and VIC reporter dyes, respectively. Probes and
rimers were obtained from Applied Biosystems;
LR9 forward primer 5=-TGC AGC CGG AGA
GT TTG-3=, reverse primer 5=-CGC GGT AGC
CC GTG AAT-3=, probe 6FAM-CAG TCA ATG
CT CC-MGB NFQ used at a ﬁnal concentration of
00 nM and 200 nM, respectively. Control reagents
ere used as per the predeveloped TaqMan Assay
eagent for Human TBP (Applied Biosystems). Real-
ime PCR ampliﬁcation and product detection was
erformed using an ABI PRISM 7700 Sequence De-
ection System (Applied Biosystems) as recommended
y the manufacturer. The quantity of cDNA for each
NA sample was normalized to the quantity of TBP
DNA in each sample. Relative expression was deter-
ined using 		Ct (threshold cycle) method accord-
ng to the manufacturer’s protocol. Each assay in-
ludes a ﬁxed standard, a no-template control, and
DNA samples in triplicate.
valuation of Clinical Presentation and
herapeutic Response
Clinical presentation and therapeutic response
ere determined at each treating center by the phy-
ician and data manager who were blinded to the
andomization. The patient’s response status was then
onﬁrmed in a central review by an expert panel re-
iewing the data submitted, which included digital
hotographs. The expert panel was blinded to the
tatus of the patients in regard to whether the patient
as enrolled as having cGVHD or as a non-cGVHD
ontrol, whether the patient was randomized to the
lacebo or hydroxychloroquine arm, and also in re-
ard as to whether the patient was classiﬁed as a
esponder or nonresponder. The central view com-
ittee made the ﬁnal determination as to each of these
riteria.
tatistical Analysis
Descriptive statistics were generated on all data
sing Prism version 4 for PC (GraphPad Software,
an Diego, CA). The percentage change in cell sur-
ace molecule expression was deﬁned as the difference
n the percentage of positive cells after culture with
timulation and the percentage of positive cells after
ulture in otherwise identical conditions with no stim-
lation. The degree of dispersion from the mean was
alculated as a standard deviation (
). Signiﬁcance of
bserved changes was determined using Mann-Whit-
ey U, Wilcoxon rank, F-test. Chi-square, Fishers
xact, and t test as felt appropriate by the statistician
M.K.). The alpha (P) value was set at .05, making all
-values .05 statistically signiﬁcant. Even when a P
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K. She et al.390alue of .05 was seen, results were not considered
iologically signiﬁcant unless the difference was either
0% higher or lower in the GVHD value compared to
he control value.
ESULTS
ost-BMT B Cell Reconstitution of Responses to
S-Modified CpG in Patients without cGVHD
PBMC were stimulated with PS-modiﬁed CpG
006 for 48 hours in vitro, and responses were evalu-
ted in B cells by gating on CD19/CD33 cell
opulations and evaluating for expression of CD80
nd CD86. Percentage expression of CD80 and CD86
y unstimulated B cells before incubation in PS-mod-
ﬁed CpG 2006 was not signiﬁcantly different in any
f the samples (data not shown). PS-modiﬁed CpG
006 induced CD19 B cell responses were evaluated
n non-cGVHD control patients at 3, 6, 12, and 15
onths post-BMT time points to determine whether
here were any post transplant differences associated
ith functional immune reconstitution over time.
hese evaluations revealed no differences in the up-
egulation of CD80 or CD86 in response to PS mod-
ﬁed CpG 2006 between the 3 and 6 month or the 12
nd 15 months in non-cGVHD controls (data not
hown). However, there was a signiﬁcantly lower per-
entage of B cells capable of upregulating CD86 in the
-month non-cGVHD controls (n  9, 15.8% 
.2%) compared to both the 12-month (n  8,
2.8%  4.6%, P  .006) and 15-month non-
GVHD controls (n  5, 44.2%  6.3%, P  .02).
ased on this difference, all subsequent evaluations
etween control and cGVHD patients were divided
nto early onset (between 3 and 8 months upon
GVHD diagnosis; n 36, 5.7 1.7 months) and late
nset (9 months upon cGVHD diagnosis; n  15,
4.3  6 months) groups, based on the midpoint
etween the 6 month and 12 month time points. The
arly and late cGVHD time points were compared to
he 6- and 12-month non-cGVHD controls, respec-
ively.
ncreased Percentages of B Cells Respond to PS
pG after cGVHD Diagnosis
PS-modiﬁed CpG-induced B cell responses in pa-
ients with cGVHD were then evaluated and com-
ared to the non-cGVHD controls. A signiﬁcantly
reater percentage of B cells from early cGVHD (n 
9, 56.3  2.0%) group were capable of upregulating
D86 compared to 6- month non-cGVHD controls
n  9, 15.8  8.2%, P  .0004) in response to
S-modiﬁed CpG 2006 (Figure 1B). There was no
igniﬁcant difference in CD86 upregulation in the late
GVHD group compared to the 12-month controls.
o a lesser extent, a signiﬁcantly greater percentage of Pcells from early (3-8 month) cGVHD patients was
apable of upregulating CD80 (n  19, 6.7  2.3%)
ompared to control non-cGVHD patients evaluated
t 6 months post-BMT (n  9, 0.3  1.2%, P  .02)
n response to 48 hours of stimulation with PS mod-
ﬁed CpG 2006 (Figure 1C). There was no difference
n B cell CD80 upregulation between the late (9
onth) cGVHD patients compared to control non-
GVHD patients evaluated at 12 months post-BMT.
here was no signiﬁcant difference in the B cell up-
egulation of the surface expression of CD40 (data not
hown) as measured by mean ﬂuorescence intensity in
esponse to stimulation with PS-modiﬁed CpG 2006
etween all groups.
To determine if non-B cell TLR9 expressing pop-
lations were affecting B cell response to PS CpG
BMC from a limited subset of patients were depleted
f monocytes and dendritic cells prior to stimulation
ith PS modiﬁed CpG. B cell responses were identical
egardless of the presence of dendritic and mononu-
lear cells (data not shown). Proliferation assays were
onducted with B cells enriched by negative selection
s results of whole cultures between individuals not
eing consistent with results from B cells enriched by
egative selection. Enriched B cells from patients di-
gnosed with cGVHD (n  5, 7404  2309 	CPM)
ended toward a greater mitogenic response compared
o controls (n  5, 1622  634 	CPM, P  .06)
Figure 1D).
he Increased CpG Response Correlates with
LR9 Expression
PS-modiﬁed CpG represents a modiﬁcation of the
ative PD backbone of the CpG oligodeoxynucleotide
hat increases resistance to degradation from DNAse
llowing for a longer plasma half-life and higher ther-
peutic potential for in vivo administration. Recently,
t has been shown that PS-modiﬁed CpG can induce B
ell activation through both a TLR9-dependent and
independent pathway [30], whereas native PD CpG
ore closely resembles the natural ligand of TLR9
nd only activates through TLR9.
To evaluate whether response in Figure 1B was
ecause of activation through TLR9 rather than a
LR9-independent pathway, we correlated the B cell
D86 expression response to PS-modiﬁed CpG 2006
timulation (Figure 1B) from patients with newly di-
gnosed cGVHD and non-GVHD controls with ex-
ression of TLR9 mRNA levels in puriﬁed B cells as
ssessed by quantitative real-time PCR in those pa-
ients where adequate blood volume allowed for B cell
uriﬁcation. There was a signiﬁcant correlation (n 
2, r2  .65, P  .002) between PS-modiﬁed CpG
006 response and B cell TLR9 mRNA levels (Figure
A). This correlation appears to conﬁrm that TLR9
igation is a primary pathway for B cell response to
S-modiﬁed CpG 2006 stimulation.
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TLR9 Response in Chronic GVHD 391To further evaluate that the response observed in
igure 1B was TLR9 dependent, we stimulated B cells
rom the later patients enrolled in the study with native
D CpG 2006 that has the same nucleotide sequence as
S-modiﬁed CpG 2006 but lacks the backbone modiﬁ-
ation that confers non-TLR9-mediated activity and
valuated CD86 expression. Unlike PS-modiﬁed CpG
006, evaluation of native PD CpG 2006 stimulation of
BMC from non-cGVHD control patients revealed that
igure 1. Increased percentage of B cells rapidly responds to PS-m
xpression of CD86 by subgated CD19 B cells after culture wit
atients. PBMC were cultured with PS-modiﬁed CpG 2006 or m
D19/CD33 cells and the expression of CD86 (B) or CD80 (C
CD80 or CD86) by PS-modiﬁed CpG-stimulated cells minus perce
agnetic sorting were pulsed with 1 Ci [3H] thymidine 28 hours a
roliferation was assessed by [3H] incorporation.here were no time-dependent differences in B cell oD80 and CD86 (data not shown) upregulation at 3, 6,
2, or 15 months post-BMT in contrast to PS-modiﬁed
pG 2006 stimulation (Figure 1B).
Identical to PS-modiﬁed CpG response in patients
ith cGVHD, there were a signiﬁcantly greater per-
entage of B cell upregulated CD86 in the early
GVHD group (n  6, 30.7  6.0%) compared to
ontrols (n  6, 7.7  5.3%, P  .02) (Figure 2B).
oreover, there was signiﬁcantly greater percentage
CpG after cGVHD diagnosis. (A) Representative FACS plots for
ithout stimulation with PS-modiﬁed CpG in cGVHD or control
nly for 48 hours and evaluated by ﬂow cytometry by gating on
ults are expressed as the difference between percentage expression
xpression in those cultured in media. (D) B cells isolated by negative
rt of incubation for 20 hours in PS-modiﬁed CpG or media alone.odiﬁed
h or w
edia o
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K. She et al.392pregulating CD86 in the late cGVHD group (n  3,
0.9  0.8%) compared to non-cGVHD 12-month
ost-BMT controls (n  5, 7.6  1.9%, P  .003)
Figure 2B). Similar to the PS-modiﬁed CpG re-
ponse (Figure 1D), a signiﬁcantly greater percentage
f B cells from the early cGVHD group were capable
f upregulating CD80 compared to expression in me-
ia culture controls (n  5, 2.7  1.3%) compared to
he non-GVHD 6-month post-BMT controls (n  5,
2.8  2.1%, P  .03, data not shown). Stimulation
ith a control native PD oligodeoxynucleotide GpC
137, the reverse sequence of 2006, had a negligible
mmunologic effect (data not shown).
valuation of CpG Response as a Marker for
cute GVHD
As expected, many of the cGVHD patients had a
rior history of aGVHD in the ﬁrst 3 months follow-
ng BMT (Table 1). It was possible that the aug-
ented CpG response is not speciﬁc to cGVHD but
ather a consequence of aGVHD. Control patients
ith and without acute GVHD were compared for B
ell response to PS-modiﬁed CpG 2006 (Figure 3) and
Figure 1. (continued)ative PD CpG 2006 (data not shown) at 3 and 6 wonths post-transplant. cGVHD patients with and
ithout a previous history of aGVHD were also com-
ared. Although the numbers of control patients with
GVHD are limited, the response by these patients
ere not strikingly different compared to their fellow
ohorts, and there was no difference in response be-
ween cGVHD patients regardless of their aGVHD
ackground. Of the control patient samples with a
obust PS modiﬁed CpG response at 3 months post-
MT, all patients that were available at 6 months and
ater had attenuated CpG responses. None of the
ssessed non-GVHD control patients subsequently
eveloped cGVHD by the time of the study’s closure.
dditionally, B cell CD86 responses to native PD
igure 2. Dependence of CpG response on TLR9. (A) TLR9
RNA expression was quantiﬁed by real-time PCR from CD19
ells isolated by negative magnetic sorting. Correlation between
LR9 mRNA expression and CD19 B cell upregulation of CD86
fter culture with PS CpG 2006 stimulation compared to culture
ithout stimulation as evaluated in Figure 1B. (B) PBMC were
timulated with native PD CpG for 48 hours and evaluated for
D86 expression as in Figure 1. Early-onset (3–8 months) cGVHD
atients (open square) were compared to 6 month controls (open
ircle), late onset (9 months) of cGVHD patients (closed square)
ere compared to 12 month controls (closed circle).
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TLR9 Response in Chronic GVHD 393pG 2006 from nontransplant adult volunteers (n 
) were comparable to non-GVHD control patients
egardless of time post-BMT (data not shown).
Cell Responses to Ligation of Other Toll-Like
eceptors
It was possible that the increased responsiveness of
cells from cGVHD patients results from a general
pregulation of TLR receptors. To evaluate this we
timulated B cells with PG, an agonist of the het-
rodimer of TLR2 and TLR6 that is expressed at the
cell surface, and LPS, an agonist of TLR4. LPS
cted as a negative control for B cells, whereas TLR4,
he receptor for LPS, expressed by murine B cells, is
ot present in human B cells [26]. Consequently, in
ononuclear assays, any B cell response would be
econdary to the effects of LPS recognition by other
esponder cell populations. There were no signiﬁcant
ifferences in B cell response to TLR2/6 ligation by
G stimulation (data not shown) within either the
igure 3. Evaluation of CpG response as a marker for aGVHD
ontrol patients with (closed) and without (open) aGVHD were
ompared for B cell response to PS-modiﬁed CpG 2006 at 3
onths (diamond) and at 6 months (circle). cGVHD patients with
closed) and without (open) previous aGVHD were also compared
square).
able 2. B Cell and Subpopulations
Early Onset (3-8 mo)
cGVHD
(n  25)
6 mo No GV
(n  14)
cells/mL PB*
Median (Range) 3.9  105 (0.009–36) 1.5  105 (0–
Mean (SD) 6.8  105 (9.3) 2.2  105 (2.
B cells CD28 Memory
Mean (SD) 3.9% (0.8) 2.5% (1.
B cells CD5 B-1
Mean (SD) 26.5% (5.4) 17.3% (5.PB, peripheral blood.GVHD or the non-GVHD control groups regard-
ess of time post-BMT. There were no differences
etween the non-GVHD 6 months post-BMT con-
rols (n  4, 12.1  11.8%) compared to the aggre-
ate of the cGVHD groups (n  5, 18.6  7.0%, P 
73). Likewise, there were no differences in B cell
esponse to TLR4 ligation by LPS stimulation within
ither the cGVHD or control groups regardless of the
ime post-BMT. There was no difference between the
-month post-BMT non-cGVHD controls (n  3,
.63  8.7%) and the aggregate of the cGVHD
roups (n 25, 6.6 2.8%, P .88). There appeared
o be no generalized upregulation of B cell response to
ither TLR2/6 through PG stimulation or to second-
ry signals resulting from LPS stimulation of TLR4
xpressing non-B cell populations.
Cell Subpopulations
It has been suggested that CD27-positive memory
cells respond more rapidly to CpG stimulation [31],
nd that CD5-positive B-1 B cells, capable of produc-
ng low-afﬁnity autoreactive antibodies, have a role in
arious autoimmune diseases [32], although not the
ource of autoantibodies in a murine GVHD model
33]. There were depressed absolute number of circu-
ating B cells in the 6-month control non-cGVHD
atients compared to the early-onset cGVHD group,
ut absolute B cell counts were comparable between
he late cGVHD group and non-GVHD 12-month
ontrols (Table 2). Although absolute numbers of
oth CD27 and CD5 B cells were decreased in the
-month post-BMT non-GVHD control groups
ompared to the early cGVHD group, these decreases
ere secondary to reduced numbers of total B cells.
owever, the ratio of these populations compared to
he entire B cell pool was identical in all groups (Table
). These B cell subpopulations did not preferentially
roliferate in response to CpG stimulation compared
o other B cells, as there were no differences in the
hange in percentage of these B cell subpopulations
fter stimulation (data not shown).
P
Value
Late Onset (>9 mo)
cGVHD
(n  16)
12 mo No GVHD
(n  6)
P
Value
ns 2.3  105 (0–50) 1.8  105 (0.063–8.4) ns
6.4  105 (12) 2.2  105 (2.3)
ns 7.1% (2.3) 4.3% (0.7) ns
ns 17.7% (5.1) 25.2% (13.4) nsHD
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K. She et al.394iagnosis of cGVHD Severity and Clinical
eatures and CpG Response
cGVHD has a large heterogeneity in tissue in-
olvement, and it was possible that the CpG B cell
esponse was more closely associated with 1 particular
linical presentation of cGVHD. A univariate analysis
evealed that there was no relationship between B cell
esponse to PS-modiﬁed or native PD CpG response,
nd the total number of organs affected by cGVHD or
y the location of organ involvement when assessing
GVHD as classiﬁed for joint, skin, oral, liver, esoph-
gus, lower gastrointestinal tract, weight, pulmonary,
r absolute eosinophils count. None of the clinical
resentations were closely correlated as a particular
anifestation with the CpG B cell response. The
iming of onset of cGVHD was not statistically sig-
iﬁcantly related to the number of organs involved,
he speciﬁc organ involved, or the constellation of
rgans involved.
linical Response to Treatment and Changes
n CpG Response
A subset of cGVHD patient samples was available
or CpG response evaluation 2 months after the start
f cGVHD treatment. Peripheral blood samples col-
ected 2 months after initiation of protocol treatment
as compared to the clinic classiﬁcation of response
one at 9 months after enrollment in protocol. In this
roup of patients, approximately the same proportion
f patients received standard therapy (cyclosporine/
rednisone  placebo) and the experimental arm (cy-
losporine/prednisone  hydroxychloroquine). B cell
D86 responses to PS-modiﬁed CpG 2006 was as-
essed in an identical manner as previously. There was
trend towards decreased CpG response, as evaluated
y B cell upregulation of CD86, in the patients who
ere evaluated as being in either a complete (CR) or
artial (PR) remission (n  4, 34.2%  9.1%) com-
ared to those patients with no response (NR) to
herapy (n  8, 57.0%  4.3%, P  .07) (Figure 4).
ecause hydroxychloroquine is a potent inhibitor of
pG activation through TLR9, it was possible that
he decrease in CpG response in the CR and PR
atients resulted from only exposure to hydroxychlo-
oquine. To evaluate this possible effect, we evaluated
or differences at 2 months after initiation of therapy
n the patients who received cyclosporine, prednisone,
nd hydroxychloroquine (hydroxychloroquine group)
ersus those who received cyclosporine, prednisone,
nd placebo (placebo group) for differences in the
pG response in B cells. There were no signiﬁcant
ifferences in PS-modiﬁed CpG response between
atients treated with placebo in addition to standard
herapy compared to patients treated with hydroxy-
hloroquine in addition to standard therapy, consis- aent with the subcellular half-life of hydroxychloro-
uine.
ISCUSSION
The development of cGVHD appears to be asso-
iated with an increase in the number of B cells ex-
ressing a high level of TLR9, resulting in increased
ensitivity to microorganism-derived immunostimula-
ory CpG. A subset of patients, the early-onset
GVHD group, deﬁned as being diagnosed with
GVHD between 3 and 8 months post-transplant,
ossess greater percentage of circulating B cells that
an rapidly upregulate costimulatory molecules in re-
ponse to PS-modiﬁed CpG compared to time-
atched allo-BMT non-cGVHD control patients.
he late-onset cGVHD group, those patients who
ere diagnosed with cGVHD at or after 9 months
ost-transplant, also possessed a robust percentage of
cells that can rapidly respond to PS-modiﬁed CpG
hat was comparable to the early-onset group. How-
ver, there were no statistically signiﬁcant differences
n response when compared to responses by time-
atched controls, as the increased percentage of PS-
odiﬁed CpG responsive B cells was associated with
n increase in the length of time after transplantation
n non-cGVHD control patients.
Although the response to PS-modiﬁed CpG cor-
elated with B cell expression levels of TLR9 mRNA,
he stable response to native PD CpG in the late
ontrol group compared to the early non-cGVHD
ontrol group and the consistent robust response by
igure 4. Clinical response to therapy and CpG response. cGVHD
atients were evaluated for B cell CD86 upregulating in response to
S-modiﬁed CpG stimulation 2 months after the start of treatment.
atients who were evaluated as responders (N  3 CR and 1 PR) at
months (plus) were compared to cGVHD patients who had no
esponse (N  7) to therapy at 9 months (star).ll cGVHD patients suggests that the increased re-
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TLR9 Response in Chronic GVHD 395ponse to PS CpG by the late control group results
rom non-TLR9-dependent mechanisms. The differ-
nces in response to PS-modiﬁed and native PD CpG
uggests that the native PD CpG is a more physiolog-
cally relevant assay of TLR9 function, and that the
obust response to PS-modiﬁed CpG by the late con-
rol group may not translate to an enhanced response
o naturally occurring and clinically relevant immuno-
timulatory CpG DNA. As there were no striking
ifference in CpG response between patient cohorts
ith and without a previous history of aGVHD, and
hat there were cGVHD patients who were diagnosed
ell past the time frame for aGVHD development,
he likelihood that the altered CpG response is from
olely a previous history of aGVHD is low. These
ndings suggest that a persistent robust CpG response
s a characteristic of extensive cGVHD, and could be
elevant in the etiology or maintenance of disease.
It was probable that the TLR9 high-expressing B
ell population represented a B cell subpopulation that
as previously been associated with development of
utoimmune or inﬂammatory responses. Memory B
ells have been reported to constitutively express high
evels of TLR9, and are capable of more rapidly re-
ponding to CpG compared to naïve resting B cells;
he percentage of B cells with a CD27 memory
henotype was comparable across all cGVHD and
on-cGVHD groups. Although B-1 B cells have been
mplicated in some autoimmune diseases, there were
imilarly comparable percentages of B cells with a
D5 B-1 phenotype across all groups. These ﬁnd-
ngs support the hypothesis that there may be a unique
LR9 high-expressing population that is both primed
or the induction of alloreactive T cells in cGVHD as
ell as predisposed to generate antigen speciﬁc anti-
ody responses.
Activated T cells are the primary mediators of
GVHD. However, T cell activation is contingent on
he presentation of recognizable host antigen in con-
unction with costimulatory signals, both of which are
rimarily provided by professional APC. Additionally,
istologic examination of affected tissues in patients
ith cGVHD shows the colocalization of T cells and
ostimulatory molecule expressing B cells [34]. Here
e have observed that in patients with newly diag-
osed cGVHD there is a greater percentage of pe-
ipheral blood B cells that are capable of rapidly re-
ponding to immunostimulatory CpG by upregulating
ostimulatory molecules. We have observed a robust
pregulation of CD86, and to a lesser extent CD80,
y B cells induced by TLR9 ligation by CpG ODNs.
D86 is an important molecule for activating naïve T
ells [35], and CD80 is involved in delayed after-cell
ctivation and primarily for T cells that have already
een primed to antigen [36]. It is tempting to specu-
ate that with a greater percentage of B cells capable of
esponding to CpG-mediated danger signals there is rn increased chance that a potentially host-reactive B
ell can be activated and be able to subsequently ac-
ivate their cognate T cell. Additionally, the idea that
ncreased sensitivity to CpG may drive autoantibody
esponses in B cells is supported by the recent report
hat T helper cell induction of antigen speciﬁc anti-
ody responses in B cells requires TLR ligation [37].
Contrary to other reports [38], a subset of our
ohort of cGVHD patients appeared to have an ac-
elerated reconstitution of B cells, although acceler-
ted B cell recovery is associated with elevated auto-
ntibody levels and extensive cGVHD [39]. Many of
he previous studies were performed on patients with
stablished cGVHD, whereas the current study eval-
ated patients at the time of initial presentation of
xtensive cGVHD. Nevertheless, as CpG response
as evaluated as the percentage of B cells upregulating
o-stimulatory molecules, the differences in CpG re-
ponse are not dependent on the absolute number of B
ells.
Although the number of evaluable samples at 2
onths after initiation of therapy for cGVHD was
imited for correlation with response, we still observed
trend toward a drop in the PS modiﬁed CpG re-
ponse in B cells and classiﬁcation of a partial or
omplete response in patients at 9 months. Currently
here is a paucity of available biomarkers in cGVHD
40]. These data suggest that the CpG response may
e useful as a biomarker for both the diagnosis and
valuation of response in cGVHD therapy. Further
valuations with larger studies in both children and
dults are required to conﬁrm this potential applica-
ion and to further explore the association of increased
pG response and disease.
The increased CpG response appears to be pri-
arily mediated by increased expression of TLR9
xpression. There are several potential etiologies that
ay result in expansion of a TLR9 high-expressing B
ell population post-BMT. These include CD40 liga-
ion, exposure to microbial products such as Saccharo-
yces aureus, or B cell receptor engagement [41]. Do-
or TLR9 genotype polymorphisms that lead to
igher gene expression may also be an underlying
actor [42]. The intriguing association of B cell TLR9
RNA expression and the levels of plasma anti-
sDNA antibody remain to be conﬁrmed in a larger
ohort of patients. However, whether increased TLR9
unction facilitates the production of anti-dsDNA an-
ibody [43] or whether the presence of such antibodies
pregulates TLR9 expression [44] will have to be
etermined. Elucidation of the role of CpG responses
nd TLR9 expression in B cells and other antigen
resenting cells populations in cGVHD must be pur-
ued as such investigations may lead to an increased
nderstanding of the mechanisms important in
GVHD. Meanwhile, TLR9 expression and B cell
esponse to native PD CpG has emerged as a poten-
t
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K. She et al.396ially useful biomarker for diagnosis, prognosis, or as a
herapeutic response indicator for cGVHD.
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